Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC settlement

This article was originally published in The Tan Sheet

Executive Summary

FTC announces Nov. 28 HeightMax Plus maker Sunny Health Nutrition Technology & Products will pay $375,000 to settle charges its advertising claims are deceptive. The settlement also holds the Riverview, Fla.-based company potentially liable for $1.9 mil. in the event it "misrepresented their finances," the release says. Claims include a regular intake of dietary supplement HeightMax results in a 10% to 25% gain in height. The company is also charged with inventing "William Thomson," who was presented in HeightMaxads as an expert with a PhD in Biochemistry. Other products included in the complaint are HeightMax Concentrate, Liposan Ultra Chitosan Fat Blocker and Osteo-Vite. Radio and print advertisements ran in Spanish and English and appeared in Newsweek, Rolling Stone and Maxim...

You may also be interested in...

Avalanche clause in effect

FTC on April 24 says HeightMax maker Sunny Health Nutrition Technology & Products must pay its full $1.9 mil. redress for making false and unsubstantiated claims for three dietary supplements. In November, the Riverview, Fla.-based firm said it would pay $375,000 of the settlement agreement due to inability to pay the full amount (1"The Tan Sheet" Dec. 4, 2006, In Brief). However, the avalanche clause included in the settlement states the company must pay the entire $1.9 mil. if the firm misrepresented its finances. FTC said in December it discovered Sunny Health Nutrition possessed an undisclosed PayPal account containing more than $1.8 mil...

Roche/Genentech Keeps Commitment To External Cancer Innovation

Roche/Genentech oncology partnering maintained a robust dealmaking pace through the pandemic, keeping the percentage of partnered R&D programs at about 50% of the cancer drug pipeline.

US FDA Eases Changes For Certain Sterile Injectable Container Closure Materials

To mitigate pandemic disruption of component supply chains, the US FDA said it will downgrade some post-approval change categories for sterile drug container closure systems. The downgrade will cover drugs in shortage and those used to treat COVID-19.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts